Stem Cell Therapeutics Corp.

Stem Cell Therapeutics Corp.

October 05, 2006 23:59 ET

Stem Cell Therapeutics Corp. Announces Formation of Clinical Advisory Board

CALGARY, ALBERTA--(CCNMatthews - Oct. 5, 2006) -


Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT") is pleased to announce the formation of its Clinical Advisory Board (CAB) with three internationally renowned clinicians. Drs. Steven Cramer, Hannelore Ehrenreich, and Michael Hill have agreed to provide input and guidance on SCT's current stroke program with NTx™-265, as well as potential future programs in Schizophrenia, Multiple Sclerosis, Traumatic Brain Injury, and Huntington 's disease.

Dr. Steven Cramer is an Associate Professor of Neurology and Anatomy & Neurobiology at the University of California, Irvine (UCI). He is board certified in Internal Medicine, Neurology, and Vascular Neurology, and directs the UCI Medical Center Stroke Center. Other contributions include Associate Clinical Director for the UCI Stem Cell Research Center and Director of the Neuroimaging Core of the General Clinical Research Center. His research interests focus on recovery of function after central nervous system (CNS) injury, particularly recovery of movement. Some of Dr. Cramer's studies have examined the mechanisms underlying recovery after CNS injury, particularly in subjects with stroke or spinal cord injury. Dr. Cramer's current work is focused on applying these insights to maximize gains from restorative interventions. Restorative therapies under study in Dr. Cramer's lab include: cell therapy, small molecules to modulate specific neurochemical systems, neurotrophic factors, brain stimulation, motor imagery, and robotic therapy.

Dr. Hannelore Ehrenreich graduated in medicine and veterinary medicine specializing in clinical neurology and psychiatry at the universities of Hanover and Munich, Germany. From 1989-1992 she was a postdoctoral fellow at the National Institute of Allergy and Infectious Disease, National Institute of Health, USA. Dr. Ehrenreich is now a Professor of Psychiatry and Neurology at the Max-Planck-Institute of Experimental Medicine and the University of Goettingen, Germany. For over 15 years she has been performing translational medicine, working on novel concepts for the treatment of neuropsychiatric disease, including alcoholism (treatment and regeneration after abstinence), brain disorders (ischaemia/oxygen deficiency, neurotrauma), and the regulation of vasoactive factors in the CNS. Since 1994 she has been investigating the neuroprotective and neuroregenerative effects of erythropoietin in brain disease. She has over 120 publications in peer-reviewed international journals.

Dr. Michael Hill received undergraduate training in Biochemistry at McGill University, completed medical school and an internal medicine residency at the University of Ottawa and undertook further residency training in neurology at the University of Toronto. At the University of Calgary, Dr. Hill completed fellowship training in Stroke Neurology and received a Master's degree in Clinical Epidemiology. Dr. Hill is currently primarily appointed as Associate Professor in the Department of Clinical Neurosciences with cross-appointments to Medicine and Community Health Sciences at the University of Calgary. Dr. Hill's areas of research interests include clinical trials in stroke and the use of administrative data for stroke research and surveillance. He has participated in multiple clinical trials, leads the Calgary Stroke Program Clinical Trials Group and is leading four large clinical trials as the Principal Investigator (PI), co-PI or Steering Committee member.

"We are delighted to have such esteemed and renowned clinicians agree to form the nucleus of our Clinical Advisory Board," commented Dr. Alan Moore, Chief Clinical and Regulatory Officer of SCT. "As we rapidly advance through the clinic with our stroke program, and look to develop other programs, this advisory board will be invaluable in providing input and guidance to ensure success."

About NTx™-265: NTx™-265 is a therapeutic regimen of two drugs being developed by SCT for the treatment of stroke. Human chorionic gonadotropin (hCG) is the first drug administered in the regimen, and aims to increase the number of neural stem cells (NSCs) located in the brain of a patient suffering from a recent stroke. Erythropoietin (EPO) is the second drug administered in the regimen, and aims to promote the differentiation of these newly formed NSCs into new neurons. New neurons thus formed are anticipated to provide benefit to the patient through the replacement of the brain cells that were lost or damaged by the stroke.

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. (SCT) is a biotechnology company focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The company's programs aim to repair neurological function lost due to disease or injury. Our currently enrolling phase IIa clinical program for NTx™-265 targets the treatment of stroke by repurposing approved and clinically well defined drugs. The company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information